Valuation: Axogen, Inc.

Market Cap 2.23B 1.99B 1.84B 1.67B 3.13B 212B 3.18B 22.16B 8.77B 111B 8.38B 8.2B 350B P/E 2026 *
-96.4x
P/E 2027 * 346x
Enterprise Value 2.23B 1.99B 1.84B 1.67B 3.13B 212B 3.18B 22.16B 8.77B 111B 8.38B 8.2B 350B EV / Sales 2026 *
7.82x
EV / Sales 2027 * 6.08x
Free-Float
97.6%
Yield 2026 *
-
Yield 2027 * -
1 day+3.76%
1 week+6.82%
Current month-9.21%
1 month-14.55%
3 months-3.33%
6 months+2.86%
Current year+16.28%
1 week 34.11
Extreme 34.11
38.33
1 month 34.11
Extreme 34.11
44.68
Current year 27.54
Extreme 27.54
52.91
1 year 17.14
Extreme 17.14
52.91
3 years 3.45
Extreme 3.45
52.91
5 years 3.45
Extreme 3.45
52.91
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 09/08/2024
Director of Finance/CFO 42 12/05/2025
Chief Operating Officer 65 10/01/2025
Director TitleAgeSince
Director/Board Member 65 01/09/2016
Director/Board Member 58 15/05/2019
Chairman 70 09/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Sell

Director

-3,500 0.0065%
11/8/26 Exercice

Director

40,059 0.0745%
10/8/26 Exercice

Compliance Officer

202,500 0.3767%
Change 5-day change 1-year change 3-year change Capi.($)
+3.76%+6.82%+110.86%+842.08% 2.15B
-0.40%-3.25%+18.80%+45.11% 250B
+0.33%-0.43%+5.69%+11.99% 162B
+1.90%+5.71%-14.18%+69.45% 154B
-0.70%+3.51%-56.00%-8.71% 66.68B
+0.24%+2.47%-15.16%-9.00% 52.08B
+0.15%+3.20%+11.42%+61.21% 52.22B
-1.13%+1.10%+15.92%+28.20% 51.93B
-0.47%-1.41%+18.65%+58.45% 49.02B
-0.42%+2.14%+30.11%+78.86% 44.76B
Average +0.33%+1.65%+12.61%+117.76% 88.45B
Weighted average by Cap. +0.14%+0.55%+3.21%+40.39%

Financials

2026 *2027 *
Net sales 286M 255M 235M 214M 400M 27.11B 406M 2.83B 1.12B 14.19B 1.07B 1.05B 44.79B 367M 328M 303M 275M 514M 34.87B 522M 3.65B 1.44B 18.25B 1.38B 1.35B 57.61B
Net income -22.51M -20.1M -18.55M -16.84M -31.52M -2.14B -32.01M -223M -88.39M -1.12B -84.47M -82.68M -3.53B 5.56M 4.97M 4.58M 4.16M 7.79M 528M 7.91M 55.2M 21.84M 276M 20.87M 20.43M 872M
Net Debt - -
Projected Income Statement - Annual - Axogen, Inc.
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, and NerveTape. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
23/10/26 US$38.06 +3.76% 2,192,072
22/10/26 US$36.68 +0.55% 961,631
21/10/26 US$36.48 +0.86% 1,131,528
20/10/26 US$36.17 +2.64% 974,619
19/10/26 US$35.24 +1.79% 782,538
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - Axogen, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
36.68USD
Average target price
53.09USD
Spread / Average Target
+44.74%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Axogen, Inc.
  1. Stock Market
  2. Stocks
  3. AXGN Stock